Once-daily gentamicin dosing in newborn infants

Pediatrics

Volumn 103, Issue 6 I, 1999, Pages 1228-1234

  Lundergan, Faye S ^a,b,c   Glasscock, Gregory F ^a,c   Kim, Eun H ^a,c   Cohen, Ronald S ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Gentamicin; Loading dose; Neonates; Once daily dosing

Indexed keywords

CREATININE; GENTAMICIN;

ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; HUMAN; LOW BIRTH WEIGHT; MAINTENANCE THERAPY; NEWBORN; NEWBORN INFECTION; PRIORITY JOURNAL;

BACTERIAL INFECTIONS; CLINICAL PROTOCOLS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DUCTUS ARTERIOSUS, PATENT; GENTAMICINS; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; INJECTIONS, INTRAVENOUS; INTENSIVE CARE UNITS, NEONATAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 0033000289     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.103.6.1228     Document Type: Article

References (48)

1. American Academy of Pediatrics. Summaries of Infectious Diseases. In: Peter G, ed. 1997 Red Book: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics; 1997; 203:495
2. Noone P, Pattison JR, Davies DG. The effective use of gentamicin in life-threatening sepsis. Postgrad Med J. 1974;50:9-16
3. Moore RD, Leitman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93-99
4. Moore RD, Smith CR, Leitman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984;149:443-448
5. Lewis DB, Wilson CB. Developmental immunology and role of host defenses in neonatal susceptibility to infection. In: Remington JS, Klein JO, eds. Infectious Diseases of the Fetus and Newborn Infant, 4th ed. Philadelphia, PA: WB Saunders Co; 1995:20-98
6. Wilson CB. Immunologic basis for increased susceptibility of the neonate to infection. J Pediatr. 1986;108:1-12
7. Isemann BT, Kotagal UR, Mashni SM, Luckhaupt EJ, Johnson CJ. Optimal gentamicin therapy in preterm neonates includes loading doses and early monitoring. Ther Drug Monit. 1996;18:549-555
8. Semchuk W, Shevchuk YM, Sankaran K, Wallace SM. Prospective, randomized, controlled evaluation of a gentamicin loading dose in neonates. Biol Neonate. 1995;67:13-20
9. Lui K, Bryson SM, Irwin DB, Costello S. Evaluation of Bayesian forecasting for individualized gentamicin dosage in infants weighing 1000 g or less. Am J Dis Child. 1991;145:463-467
10. Gal P, Ransom JL, Weaver RL. Gentamicin in neonates: the need for loading doses. Am J Perinatol. 1990;7:254-257
11. Watterberg KL, Kelly HW, Angelus P, Backstrom C. The need for a loading dose of gentamicin in neonates. Ther Drug Monit. 1989;11:16-20
12. Landers B, Berry PL, Kearn GL, Kaplan SL, Rudolph AJ. Gentamicin disposition and effect of development of renal function in the very low birth weight infant. Dev Pharmacol Ther. 1984;7:285-302
13. Dahl LB, Melby K, Gutteberg TJ, Storvold G. Serum levels of ampicillin and gentamycin in neonates of varying gestational age. Eur J Pediatr. 1986;145:218-221
14. Skopnik H, Wallraf R, Nies B, Tràster K, Heimann G. Pharmacokinetics and antibacterial activity of daily gentamicin. Arch Dis Child. 1992;67: 57-61
15. Blaser J. Efficacy of once-and thrice-daily dosing of aminoglycosides in in vitro models of infection. J Antimicrobial Chemother. 1991;27:21-28
16. Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande M. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis. 1988;158: 7-12
17. Vogelman B, Gudmundsson S, Turnbridge J, Leggett J, Craig WA. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis. 1988;157:287-298
18. Isaksson B, Nilsson L, Maller R, Sörén L. Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method. J Antimicrob Chemother. 1988;22:23-33
19. Baquero F, Culebras E, Patrón C, Pérez-Díaz JC, Medrano JC, Vicente MF. Postantibiotic effect of imipenem on gram-positive and gram-negative micro-organisms. J Antimicrob Chemother. 1986;18:47-59
20. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe M. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989;45:22-27
21. Giuliano RA, Verpooten GA, Verbist L, Wedeen RP, De Broe ME. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther. 1986;236:470-475
22. Beaubien AR, Ormsby E, Bayne A. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration. Antimicrob Agents Chemother. 1991;35: 1070-1074
23. Tran Ba Huy P, Defferennes D. Aminoglycoside ototoxicity; influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta Otolaryngol. 1988;105:511-515
24. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal drug use. Antimicrob Agents Chemother. 1991;35:117-123
25. Daikos GL, Jackson GG, Lolans VT, Livermore DM. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis. 1990;162:414-420
26. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996;37:645-663
27. Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312:338-345
28. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995; 39:650-655
29. Rodman DP, Maxwell AJ, McKnight JT. Extended dosage intervals for aminoglycosides. Am J Hosp Pharm. 1994;51:2016-2021
30. Gilbert DN. Once daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991;35:399-405
31. Prins JM, Büller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993; 341:335-339
32. Ter Braak EW, De Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycosides plus β-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990;89:58-66
33. Tulkens PM, Clerckx-Braun R, Dounez J. Safety and efficacy of aminoglycosides once-a-day: experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease. J Drug Dev. 1988;1:71-82
34. Ballard JL, Khoury JC, Wedig K, Wang L, Ellers-Walsman BL, Lipp R. New Ballard Score expanded to include extremely premature infants. J Pediatr. 1991;119:417-423
35. Benitz WE, Tatro DS. The Pediatric Drug Handbook. 2nd ed. St Louis, MO: Mosby-Year Book, Inc; 1988
36. Hayani KC, Hatzopoulos FK, Frank AL, et al. Pharmacokinetics of once-daily dosing of gentamicin in neonates. J Pediatr. 1997;131:76-80
37. Skopnik H, Heimann G. Once daily aminoglycoside dosing in full term neonates. Pediatr Infect Dis J. 1995;14:71-72
38. Davies MV, Cartwright DW. Gentamicin dosage intervals in neonates: longer dosage interval-less toxicity. J Pediatr Child Health. 1998;34: 577-580
39. Romero C, et al. Once daily gentamicin dosing in neonates. Pediatr Infect Dis J. 1998;17:1169-1171
40. Hindmarsh KW, Nation RL, Williams GL, John E, French JN. Pharmacokinetics of gentamicin in very low birth weight preterm infants. Eur J Clin Pharmacol. 1983;24:649-653
41. Haughey DB, Hilligoss DM, Grassi A, Schentag JJ. Two-compartment gentamicin pharmacokinetics in premature neonates: a comparison to adults with decreased glomerular filtration rates. J Pediatr. 1980;96: 325-330
42. de Hoog M, Schoemaker RC, Mouton JW, van der Anker JN. Tobramycin population pharmacokinetics in neonates. Clin Pharmacol Ther. 1997; 62:392-399
43. Linder N, Adelman C, Levi H. Auditory nerve and brain stem evoked response thresholds in infants treated with gentamicin as neonates. Ann Otol Rhinol Laryngol. 1989;98:283-286
44. Brion LP, Bernstein J, Spitzer A. Kidney and urinary tract. In: Fanaroff AA, Martin RJ, eds. Neonatal-Perinatal Medicine. 6th ed. St Louis, MO: Mosby-Year Book, Inc; 1997:1564-1636
45. Chayasirisobhon S, Yu L, Griggs L, Westmoreland SJ, Leu N. Recording of brainstem evoked potentials and their association with gentamicin in neonates. Pediatr Neurol. 1996;14:277-280
46. Salamy A, Eldredge L, Tooley WH. Neonatal status and hearing loss in high-risk infants. J Pediatr. 1989;114:847-852
47. McCracken GH. Aminoglycoside toxicity in infants and children. Am J Med. 1986;80:172-178
48. Andronikou S, Giapros VI, Choleras VI, Papadopoulou ZL. Effect of aminoglycoside therapy on renal function in full term infants. Pediatr Nephrol. 1996;10:766-768